OPKO Health to Present at Upcoming September Conferences
August 31 2017 - 8:30AM
OPKO Health, Inc. (NASDAQ:OPK) (“OPKO” or “the
Company”), announces that management will present a corporate
update, which will include an update on its hGH development
program, at the following upcoming September 2017 investor
conferences:
2017 Wells Fargo Healthcare ConferenceDate and
Time: Thursday, September 7, 2017 at 11:10
a.m. Eastern timeVenue: Westin Boston Waterfront Hotel,
Boston, MAFormat: Company presentation
Cantor Fitzgerald Global Healthcare
ConferenceDate and Time: Monday, September 25, 2017
at 3:35 p.m. Eastern timeVenue: InterContinental New York
Barclay Hotel, New York, NYFormat: Company presentation
Ladenburg Thalmann 2017 Healthcare
ConferenceDate and Time: Tuesday, September 26, 2017
at 11:30 a.m. Eastern timeVenue: Sofitel New York Hotel, New
York, NYFormat: Company presentation
10th Annual Barrington Fall Investment
ConferenceDate and Time: Wednesday, September 27
Venue: The Palmer House Hilton, Chicago, ILFormat: One-on-One
Investor Meetings
The presentations will be webcast live and can be accessed on
the Investor Relations section of the Company’s website at
www.opko.com where they will be archived for a period of time.
About OPKO Health, Inc.
OPKO Health is a diversified healthcare company that seeks to
establish industry-leading positions in large, rapidly growing
markets. Our diagnostics business includes Bio-Reference
Laboratories, the nation's third-largest clinical laboratory with a
core genetic testing business and a 400-person sales and marketing
team to drive growth and leverage new products, including the
4Kscore® prostate cancer test and the Claros® 1 in-office
immunoassay platform. Our pharmaceutical business features
RAYALDEE, an FDA-approved treatment for SHPT in stage 3-4 CKD
patients with vitamin D insufficiency (launched in November 2016),
VARUBI® for chemotherapy-induced nausea and vomiting (oral
formulation launched by partner TESARO and IV formulation pending
FDA approval), OPK88003, a once or twice weekly oxyntomodulin for
type 2 diabetes and obesity which is a clinically advanced drug
candidate among the new class of GLP-1 glucagon receptor dual
agonists, and OPK88004, an androgen receptor modulator for androgen
deficiency indications. Our biologics business includes hGH-CTP, a
once weekly human growth hormone injection (in phase 3 and
partnered with Pfizer), and a long-acting Factor VIIa drug for
hemophilia in phase 2a. We also have production and distribution
assets worldwide, multiple strategic investments and an active
business development strategy. More information available at
www.opko.com.
Contacts:
Company
OPKO Health, Inc.
David Malina, 305-575-4100
Investor Relations
dmalina@opko.com
LHA Investor Relations
Anne Marie Fields, 212-838-3777
afields@lhai.com
or
Bruce Voss, 310-691-7100
bvoss@lhai.com
Opko Health (NASDAQ:OPK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Opko Health (NASDAQ:OPK)
Historical Stock Chart
From Sep 2023 to Sep 2024